Physician

Hematology

Raoul Tibes is an expert in the field of Hematology. He graduated from NYU School of Medicine. Raoul Tibes is a published doctor. He published 38 publications, including: 'Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.' Raoul Tibes accepts Medicare payments and is listed with Medicare.gov.

Publications

---

• Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced Leukemias.
• Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
• Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in Myeloid malignancies.
• Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
• Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents.
• BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in Myeloid malignancies.
• Emerging drugs for polycythemia vera.
• Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors.
• A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
• A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
• Effect of selection of QTc formula on eligibility of Cancer patients for phase I clinical trials.
• JAK inhibition: the key to treating myeloproliferative neoplasm?
• 18-FDG PET/CT assessment of basal Cell carcinoma with vismodegib.
• Current outlook on molecular pathogenesis and treatment of myeloproliferative Neoplasms.
• Evolution of clinical trial endpoints in chronic myeloid Leukemia: efficacious therapies require sensitive monitoring techniques.
• Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.
• The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and Acute myeloid leukemia.
• Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
• Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
• Activity of alemtuzumab in Acute myelogenous leukemia and myelodysplastic syndrome with chromosome 7 aberrations.
• Blood consult: resistant and progressive essential thrombocythemia.
• Myeloproliferative Neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies.
• Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors.
• Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
• Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.
• Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal Cell carcinoma.
• RNAi screening of the kinome identifies modulators of cisplatin response in ovarian Cancer cells.
• RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing''s sarcoma.
• Inhibition of the hedgehog pathway in advanced basal-Cell carcinoma.
• 5q- myelodysplastic Syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
• Functional proteomic profiling of AML predicts response and survival.
• PI3K/AKT pathway activation in Acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.
• Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary Leukemia specimens and hematopoietic stem cells.
• Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with Acute mye...
• Activity of alemtuzumab in patients with CD52-positive Acute leukemia.
• Tyrosine kinase inhibitors and the dawn of molecular Cancer therapeutics.

Schools

---

• New York University Med Center

Procedures Preformed

---

• Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis
• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Adrenal Gland Cancer
• Anal and Rectal Cancer
• Anemia
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Education

---

• University of Texas Health Science Center
• NYU School of Medicine
• Ludwig Maximilian University of Munich Faculty of Medicine

Hospital

---

• Mayo Clinic - Phoenix/Scottsdale, Arizona

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Irwin L. Levey, MD This Doctor is OpenDoctor Recommended.
	Dr. Andrew J. Buresh, MD This Doctor is OpenDoctor Recommended.
	Dr. Thai H. Ho, MD This Doctor is OpenDoctor Recommended.
	Dr. Adrienne D. Briggs, MD This Doctor is OpenDoctor Recommended.
	Dr. Surabhi Amar, MD
	Dr. Kelly K. Curtis, MD This Doctor is OpenDoctor Recommended.
	Dr. Ann McCullough, MD This Doctor is OpenDoctor Recommended.
	Dr. Eric E. Prommer, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Chad C. Cherington, MD This Doctor is OpenDoctor Recommended.
	Dr. Karen S. Anderson, MD
	Dr. Nandita Khera, MD This Doctor is OpenDoctor Recommended.
	Dr. Rodger E. Tiedemann, MD This Doctor is OpenDoctor Recommended.
	Dr. Karen S. Anderson, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog